Literature DB >> 18028186

Pure motor relapsing Guillain-Barré syndrome associated with anti-GM1 antibodies revealing urinary bladder cancer.

E Lagrange, O Veran, G Besson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028186     DOI: 10.1111/j.1468-1331.2007.01990.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  7 in total

1.  Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma.

Authors:  Kelly N Fahl; Stephen A Poon; Ketan K Badani; Mitchell C Benson
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

2.  Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma.

Authors:  Vishal Navani; Daniel Webster; Sion K Williams; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2013-05-31

Review 3.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

4.  A hepatic cancer patient with Guillain-Barré syndrome during the perioperative period of partial hepatectomy: a case report.

Authors:  Su-Dan Zeng; Bin Ye; Zhi-Jian Liang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  A case of paraneoplastic demyelinating motor polyneuropathy.

Authors:  Sohrab Mostoufizadeh; Maryam Souri; Jérôme de Seze
Journal:  Case Rep Neurol       Date:  2012-04-25

6.  A Case of Paraneoplastic Guillain-Barré Syndrome Associated with Squamous Cell Carcinoma of the Lung.

Authors:  Danwei Wu; Anne Liu; Esther Baldinger; Alfred T Frontera
Journal:  Cureus       Date:  2018-08-24

7.  Cancer Diagnosis and Prognosis After Guillain-Barré Syndrome: A Population-Based Cohort Study.

Authors:  Blean Girma; Dóra Körmendiné Farkas; Kristina Laugesen; Nils Skajaa; Victor W Henderson; Paolo Boffetta; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2022-07-19       Impact factor: 5.814

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.